[Vasoactive intestinal peptide in heart failure]

Area of Science:

• Cardiology
• Neuropeptide Research
• Heart Failure Pathophysiology

Background:

• Vasoactive intestinal peptide (VIP) is a neuropeptide with vasodilating, inotropic, and chronotropic effects.
• Its role in the pathophysiology of heart failure requires further investigation.

Purpose of the Study:

• To investigate the pathophysiological role of vasoactive intestinal peptide (VIP) in patients with heart failure.

Main Methods:

• Radioimmunoassay of VIP in peripheral venous blood samples.
• Study included 35 patients with heart failure due to dilated cardiomyopathy.

Main Results:

• Plasma VIP concentrations were not elevated in the overall heart failure group compared to normal.
• VIP levels varied with age and NYHA functional class, showing preservation in elderly patients.
• No correlation was found between VIP levels and echocardiographic parameters or cardiomyopathy etiology.

Conclusions:

• Plasma VIP concentration in heart failure is influenced by epidemiological and clinical factors.
• The neuropeptide's productive potential is preserved in elderly heart disease patients.
• Elevated VIP may initially aid hemodynamic balance, while decreased levels in worse conditions suggest depletion.